Updated Jul 16, 2026 · Last SEC filing 2026-06-05
MBX Biosciences, Inc. (MBX) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-05. 5 Form 8-K material event filings were reported by MBX in the last 90 days. 11 Form 144 notices of proposed sale were filed for MBX stock. InsiderAlpha tracks every MBX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001776111 |
|---|
| Form 4 filings (90d) | 12 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Form 144 notices (90d) | 11 |
| Latest Form 4 filing | 2026-06-05 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Azoulay Salomon | Chief Medical Officer | S — Open-market sale | 55.0K | $38.38 | $2.11M | SEC | |
| Azoulay Salomon | Chief Medical Officer | S — Open-market sale | 15.0K | $38.30 | $575K | SEC | |
| Azoulay Salomon | Chief Medical Officer | M — Option exercise | 15.0K | $16.00 | $240K | SEC | |
| Azoulay Salomon | Chief Medical Officer | M — Option exercise | 55.0K | $10.46 | $575K | SEC | |
| Azoulay Salomon | Chief Medical Officer | S — Open-market sale | 231 | $29.54 | $7K | SEC | |
| Hawryluk P. Kent | President & CEO | S — Open-market sale | 607 | $29.54 | $18K | SEC | |
| Hoerter Steven L. | Insider | A — Grant or award | 11.9K | $0.00 | — | SEC | |
| Hawryluk P. Kent | President & CEO | P — Open-market purchase | 18.5K | $28.41 | $526K | SEC | |
| Hawryluk P. Kent | President & CEO | M — Option exercise | 28.8K | $16.00 | $460K | SEC | |
| Hawryluk P. Kent | President & CEO | A — Grant or award | 35.2K | $0.00 | — | SEC | |
| Bartram Richard | Chief Financial Officer | A — Grant or award | 15.0K | $0.00 | — | SEC | |
| Azoulay Salomon | Chief Medical Officer | A — Grant or award | 15.0K | $0.00 | — | SEC | |
| Hawryluk P. Kent | President & CEO | M — Option exercise | 182.9K | $3.25 | $594K | SEC | |
| Hawryluk P. Kent | President & CEO | P — Open-market purchase | 20.0K | $13.64 | $273K | SEC | |
| Hoerter Steven L. | Insider | P — Open-market purchase | 20.0K | $13.25 | $265K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for MBX Biosciences, Inc. (MBX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Azoulay Salomon | 7 | $3.51M |
| Hoerter Steven L. | 4 | — |
| Aynechi Tiba | 1 | — |
| Hawryluk P. Kent | 1 | $18K |
| Stelzer Laurie | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in MBX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live MBX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.